ViroGates Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 3/6

ViroGates şirketinin toplam hissedar öz sermayesi DKK9.3M ve toplam borcu DKK5.3M olup, bu da borç-öz sermaye oranını 56.9% seviyesine getiriyor. Toplam varlıkları ve toplam yükümlülükleri sırasıyla DKK16.0M ve DKK6.6M dir.

Anahtar bilgiler

56.9%

Borç/özkaynak oranı

DKK 5.30m

Borç

Faiz karşılama oranı	n/a
Nakit	DKK 8.74m
Eşitlik	DKK 9.32m
Toplam yükümlülükler	DKK 6.64m
Toplam varlıklar	DKK 15.96m

Son finansal sağlık güncellemeleri

Recent updates

ViroGates (CPH:VIRO) Is In A Good Position To Deliver On Growth Plans

Mar 06

We're Hopeful That ViroGates (CPH:VIRO) Will Use Its Cash Wisely

Nov 21

Will ViroGates (CPH:VIRO) Spend Its Cash Wisely?

Jun 14

We're Not Very Worried About ViroGates' (CPH:VIRO) Cash Burn Rate

Sep 19

We Think ViroGates (CPH:VIRO) Can Afford To Drive Business Growth

Apr 14

We Think ViroGates (CPH:VIRO) Can Afford To Drive Business Growth

Dec 30

Finansal Durum Analizi

Kısa Vadeli Yükümlülükler: VIRO 'nin kısa vadeli varlıkları ( DKK15.8M ) kısa vadeli yükümlülüklerini ( DKK1.3M ) aşıyor.

Uzun Vadeli Yükümlülükler: VIRO şirketinin kısa vadeli varlıkları ( DKK15.8M ) uzun vadeli yükümlülüklerini ( DKK5.3M ) aşmaktadır.

Borç-Özkaynak Tarihçesi ve Analizi

Borç Seviyesi: VIRO şirketinin toplam borcundan daha fazla nakiti var.

Borcun Azaltılması: VIRO şirketinin borç/öz sermaye oranı son 5 yılda 0% seviyesinden 56.9% seviyesine yükseldi.

Bilanço

Nakit Pist Analizi

Geçmişte ortalama olarak zarar eden şirketler için, en az 1 yıllık nakit akışına sahip olup olmadıklarını değerlendiriyoruz.

İstikrarlı Nakit Pisti: VIRO şirketinin mevcut serbest nakit akışına göre bir yıldan az nakit akışı süresi bulunmaktadır.

Tahmini Nakit Akışı: Serbest nakit akışı her yıl % 4.3 oranında tarihsel oranda büyümeye devam ederse VIRO un bir yıldan az nakit akışı süresi vardır.

ViroGates Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 3/6

Anahtar bilgiler

Son finansal sağlık güncellemeleri

ViroGates (CPH:VIRO) Is In A Good Position To Deliver On Growth Plans

We're Hopeful That ViroGates (CPH:VIRO) Will Use Its Cash Wisely

Will ViroGates (CPH:VIRO) Spend Its Cash Wisely?

We're Not Very Worried About ViroGates' (CPH:VIRO) Cash Burn Rate

We Think ViroGates (CPH:VIRO) Can Afford To Drive Business Growth

We Think ViroGates (CPH:VIRO) Can Afford To Drive Business Growth

Recent updates

New major risk - Revenue size

ViroGates A/S Maintains Earnings Guidance for the Full-Year of 2024

Second quarter 2024 earnings released

First quarter 2024 earnings released

Full year 2023 earnings released

ViroGates A/S to Report Fiscal Year 2023 Results on Mar 21, 2024

New major risk - Shareholder dilution

ViroGates A/S has filed a Follow-on Equity Offering in the amount of DKK 15.077282 million.

Third quarter 2023 earnings released

ViroGates A/S Announces Positive Results from a Randomized Controlled Clinical Trial on Supar-Guided Antibody Treatment in Sepsis

Virogates Provides Earnings Guidance for 2023

Second quarter 2023 earnings released

New major risk - Market cap size

First quarter 2023 earnings released

Full year 2022 earnings released

ViroGates (CPH:VIRO) Is In A Good Position To Deliver On Growth Plans

ViroGates A/S Announces CE-IVD approval for suPARnostic® TurbiLatex on the Roche Diagnostics cobas® Pure and Pro instrument platforms

ViroGates A/S Announces Chief Financial Officer Changes

ViroGates A/S to Report Fiscal Year 2022 Results on Mar 23, 2023

ViroGates A/S Announces Executive Changes

We're Hopeful That ViroGates (CPH:VIRO) Will Use Its Cash Wisely

ViroGates A/S Announces the Publication of A New Study That Shows SsuPAR upar Causes Cardiovascular Disease

ViroGates announces CE-IVD approval for suPARnostic® TurbiLatex on the Beckman Coulter AU5800 platform

Second quarter 2022 earnings released

ViroGates A/S Provides Revenue Guidance for the Year 2022 and 2023

Will ViroGates (CPH:VIRO) Spend Its Cash Wisely?

High number of new directors

ViroGates A/S Announces Board Changes

ViroGates Announces the CE-Ivd Accreditation of Its Finger-Prick Blood-Testing Product, Suparnostic® Poc+

First quarter 2022 earnings released

ViroGates A/S announces successful finalization of the development project with DIESSE Diagnostica Senese S.p.A

Third quarter 2021 earnings released

We're Not Very Worried About ViroGates' (CPH:VIRO) Cash Burn Rate

Second quarter 2021 earnings released

ViroGates A/S and the Hellenic Institute for the Study of Sepsis Announce Positive Top-Line Results from the Save-More Study

First quarter 2021 earnings released: kr.1.37 loss per share (vs kr.2.04 loss in 1Q 2020)

We Think ViroGates (CPH:VIRO) Can Afford To Drive Business Growth

ViroGates A/S Announces Clinical Routine Use in Greece

New 90-day high: kr.94.00

ViroGates A/S Announces a New Private Hospital as Clinical Routine Customer in Spain

ViroGates A/S Announces Initiation of A Clinical Trial with Hiss to Clinically Validate Its Commercial Biomarker Test for Guiding Early Anakinra Treatment of Covid-19 Patients Across 42 Hospitals

ViroGates A/S Announces Delay in the Development and Launch of suPARnostic POC+ Product

We Think ViroGates (CPH:VIRO) Can Afford To Drive Business Growth

ViroGates A/S to Report Q3, 2021 Results on Nov 11, 2021

ViroGates A/S to Report Q2, 2021 Results on Aug 19, 2021

ViroGates Announces Receipt of the First Order from Mikkeli Central Hospital in Finland

New 90-day high: kr.67.50

Third quarter earnings released

Virogates Announces Receipt of A First Order from the University Hospital of Salamanca, A New Clinical Routine Customer in Spain

New 90-day low - kr.57.00

First half earnings released

Finansal Durum Analizi

Borç-Özkaynak Tarihçesi ve Analizi

Bilanço

Nakit Pist Analizi

Sağlıklı şirketleri keşfedin